CSTF1 Antibody

What is CSTF1 and what is its function in cellular processes?

CSTF1 (Cleavage Stimulation Factor Subunit 1) is a 50 kDa subunit of the cleavage stimulation factor (CstF), a heterotrimeric protein complex also containing subunits of 77 and 64 kDa. This complex functions as a polyadenylation factor that helps specify the processing site of pre-mRNA . CSTF recognizes G+U-rich elements located downstream of the cleavage site in pre-mRNA transcripts . The CSTF1 (CstF-50) subunit specifically interacts with the C-terminal domain (CTD) of RNA polymerase II largest subunit, providing a direct link between transcription and RNA processing machinery . This interaction is believed to be crucial for the formation of stable complexes on pre-mRNA during processing events .

What are the key specifications of commercially available CSTF1 antibodies?

CSTF1 antibodies are typically polyclonal antibodies raised in rabbits with IgG isotype . They have reactivity against human samples across different antibody suppliers, with some also showing reactivity with mouse and rat samples . These antibodies are generally supplied in liquid form, purified by affinity chromatography or antigen affinity purification, and stored in PBS buffer containing sodium azide and glycerol at pH 7.3 . The molecular weight of CSTF1 is calculated at approximately 48 kDa, though it is typically observed at 50 kDa in experimental conditions .

What applications are CSTF1 antibodies validated for?

CSTF1 antibodies have been validated for multiple research applications as detailed in the following table:

How should CSTF1 antibodies be stored for optimal performance?

CSTF1 antibodies should be stored at -20°C for long-term stability . The antibodies are typically stable for one year after shipment when properly stored . It is recommended to aliquot the antibody solution to avoid repeated freeze/thaw cycles that could degrade the antibody quality . For certain preparations, aliquoting is unnecessary for -20°C storage according to manufacturer guidelines . Some preparations contain 0.1% BSA in smaller volumes (20 μl sizes) . The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

How does the interaction between CSTF1 and RNA polymerase II regulate mRNA processing?

CSTF1 serves as a critical link between transcription and RNA processing through its interaction with the C-terminal domain (CTD) of RNA polymerase II's largest subunit . This interaction is fundamental for coordinating the timing of polyadenylation with transcription termination. Research suggests that CSTF1 binding to the CTD facilitates the positioning of the CstF complex at the G+U-rich downstream element of pre-mRNAs . This coordination ensures that cleavage and polyadenylation occur efficiently and at the correct sites. When investigating this interaction, researchers should consider using techniques such as co-immunoprecipitation with CSTF1 antibodies followed by western blotting for RNA polymerase II components, or proximity ligation assays to visualize these interactions in situ.

What are the structural domains of CSTF1 and how do they contribute to its function?

CSTF1 contains several functional domains that contribute to its role in mRNA processing. The N-terminal region (approximately amino acids 1-220) is often used as an immunogen for antibody production . This region contains important structural motifs that mediate protein-protein interactions within the polyadenylation complex. The protein also contains domains responsible for binding to the CTD of RNA polymerase II, facilitating the coupling of transcription and 3' end processing . When designing experiments to study domain-specific functions, researchers should consider using truncated variants of CSTF1 in rescue experiments after knockdown, or employing domain-specific antibodies to differentiate the roles of individual structural components.

How does CSTF1 expression vary across different cell types and tissues?

While CSTF1 is expressed in various tissues as a fundamental component of the mRNA processing machinery, its expression levels can vary across different cell types. Comprehensive immunohistochemistry data from The Human Protein Atlas project, accessible through commercial antibodies like HPA047275, provides information on CSTF1 expression patterns across numerous normal and disease tissues . CSTF1 antibodies have been validated in multiple cell lines, including HeLa, HEK-293T, A549, K-562, and NIH/3T3 , suggesting expression across diverse cellular backgrounds. For researchers investigating tissue-specific expression patterns, using validated CSTF1 antibodies for immunohistochemistry with appropriate controls is essential for reliable data interpretation and comparison across tissue types.

How should immunoprecipitation experiments with CSTF1 antibodies be designed?

When designing immunoprecipitation (IP) experiments with CSTF1 antibodies, researchers should use 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate . This ratio has been validated in cell lines such as HeLa and NIH/3T3 . The IP protocol should include:

• Preparation of cell lysates in a suitable lysis buffer containing protease inhibitors

• Pre-clearing the lysate with protein A/G beads to reduce non-specific binding

• Incubation of the lysate with CSTF1 antibody (typically overnight at 4°C)

• Addition of protein A/G beads to capture the antibody-antigen complexes

• Thorough washing to remove non-specifically bound proteins

• Elution and analysis by Western blotting

For co-immunoprecipitation studies investigating CSTF1's interactions with other proteins in the polyadenylation complex or with RNA polymerase II, milder lysis conditions may be necessary to preserve protein-protein interactions.

What controls should be included when using CSTF1 antibodies for immunofluorescence?

When performing immunofluorescence (IF) experiments with CSTF1 antibodies, several controls are essential for result validation:

• Primary antibody omission control: Include samples where the primary CSTF1 antibody is omitted but all other steps are performed

• Isotype control: Use a non-specific rabbit IgG at the same concentration as the CSTF1 antibody

• Peptide competition control: Pre-incubate the CSTF1 antibody with its immunogen peptide before application to verify specificity

• Positive control: Include HeLa cells, which have been validated for CSTF1 detection by IF

• CSTF1 knockdown or knockout control: If available, include cells with reduced CSTF1 expression

The recommended dilution range for IF is 1:50-1:500 , but optimization may be required for specific applications. Proper fixation methods (typically 4% paraformaldehyde) and permeabilization steps are crucial for accessing the nuclear CSTF1 protein. Counterstaining with DAPI or another nuclear marker is recommended to confirm the expected nuclear localization pattern of CSTF1.

How can researchers distinguish between specific and non-specific signals when using CSTF1 antibodies?

Distinguishing between specific and non-specific signals is critical for accurate interpretation of CSTF1 antibody results. For Western blot applications, the specific CSTF1 band should appear at approximately 50 kDa, which is slightly higher than the calculated molecular weight of 48 kDa . Any bands significantly deviating from this size should be scrutinized. Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide, can help identify specific bands that disappear after competition. For immunohistochemistry and immunofluorescence, specific CSTF1 staining should primarily localize to the nucleus where mRNA processing occurs. Comparison with published staining patterns from antibody validation data is helpful. Additionally, CSTF1 knockdown or knockout samples serve as excellent negative controls to confirm signal specificity across all applications.

What are common pitfalls in analyzing CSTF1 expression data and how can they be avoided?

Several common pitfalls can affect CSTF1 expression analysis:

• Cross-reactivity issues: Some CSTF1 antibodies may cross-react with similar proteins. Researchers should verify specificity through knockout/knockdown controls or peptide competition assays.

• Inconsistent loading controls: When comparing CSTF1 expression across samples, inconsistent loading can lead to misinterpretation. Using multiple housekeeping proteins or total protein staining methods provides more reliable normalization.

• Cell type variability: CSTF1 expression may vary between cell types . When comparing expression across different cell lines, appropriate positive controls for each cell type should be included.

• Antibody lot-to-lot variation: Performance may vary between antibody lots. Maintaining detailed records of antibody lots and their validation is essential for long-term studies.

• Inadequate image quantification: For immunofluorescence or IHC studies, proper image acquisition and quantification parameters must be consistent across all samples and controls.

To avoid these pitfalls, researchers should include appropriate controls, validate antibodies for their specific application, and use consistent protocols for sample preparation and data analysis.

How can researchers quantitatively analyze CSTF1 expression in Western blot and immunohistochemistry experiments?

For quantitative Western blot analysis of CSTF1:

• Use a dilution series of recombinant CSTF1 protein to create a standard curve

• Ensure sample loading is within the linear range of detection

• Use appropriate normalization to housekeeping proteins or total protein staining

• Apply densitometry software that can accurately quantify band intensity while accounting for background

• Perform at least three biological replicates for statistical validity

For quantitative immunohistochemistry:

• Use multi-tissue arrays or standardized tissue sections to minimize technical variability

• Apply validated scoring systems (such as H-score or Allred score) for semi-quantitative analysis

• Consider using automated image analysis software for more objective quantification

• Include control tissues with known CSTF1 expression levels

• Use the recommended dilutions (1:100-1:200 for IHC-P) and standardize staining protocols

For both methods, statistical analysis should include appropriate tests based on data distribution, and results should be presented with measures of central tendency and dispersion.

What strategies can resolve weak or absent CSTF1 signals in Western blot experiments?

When encountering weak or absent CSTF1 signals in Western blots, researchers should systematically address potential issues:

• Antibody concentration: Increase antibody concentration within the recommended range (1:500-1:4000) . Start with a higher concentration (1:500) and then optimize.

• Protein loading: Increase the amount of total protein loaded. CSTF1 may be expressed at low levels in some cell types.

• Transfer efficiency: Optimize transfer conditions for proteins in the 50 kDa range. Consider using PVDF membranes for better protein retention.

• Sample preparation: Ensure complete lysis and denaturation. CSTF1 is a nuclear protein, so nuclear extraction protocols may yield better results.

• Detection system: Switch to a more sensitive detection method (e.g., from colorimetric to chemiluminescence or enhanced chemiluminescence).

• Antibody selection: If one CSTF1 antibody fails, try an alternative antibody that recognizes a different epitope. The search results mention multiple antibodies targeting different regions of CSTF1 .

• Positive control: Include lysate from HeLa, HEK-293T, A549, or K-562 cells as positive controls, as these have been validated for CSTF1 detection .

How can non-specific background be reduced in CSTF1 immunostaining experiments?

To reduce non-specific background in CSTF1 immunostaining:

• Optimize blocking conditions: Increase blocking time or concentration (typically 3-5% BSA or normal serum from the same species as the secondary antibody).

• Antibody dilution: Use the recommended dilution ranges (1:50-1:500 for IF/ICC, 1:100-1:200 for IHC-P) and optimize for your specific system.

• Washing stringency: Increase the number and duration of washing steps with an appropriate buffer (e.g., PBS with 0.1-0.3% Tween-20).

• Secondary antibody concentration: Dilute the secondary antibody further if background persists despite proper primary antibody dilution.

• Autofluorescence reduction: For fluorescence applications, include an autofluorescence quenching step if tissue autofluorescence is an issue.

• Fixation optimization: Different fixation methods can affect antibody accessibility and background. Compare paraformaldehyde, methanol, or acetone fixation.

• Antigen retrieval: For IHC applications, optimize antigen retrieval methods (heat-induced or enzymatic) to improve specific signal while minimizing background.

• Endogenous peroxidase blocking: For peroxidase-based detection systems, ensure thorough blocking of endogenous peroxidase activity.

What factors should be considered when troubleshooting discrepancies between expected and observed molecular weights of CSTF1?

CSTF1 has a calculated molecular weight of 48 kDa but is typically observed at 50 kDa in experimental systems . When investigating discrepancies between expected and observed molecular weights:

• Post-translational modifications: Consider potential modifications such as phosphorylation, ubiquitination, or SUMOylation that could increase the apparent molecular weight.

• Isoforms: Check for alternative splicing variants of CSTF1 that might result in size variations.

• Gel concentration and running conditions: The percentage of the gel and running conditions can affect protein migration. Use appropriate molecular weight markers.

• Sample preparation: Incomplete denaturation or reducing conditions can affect protein migration. Ensure samples are fully denatured with adequate reducing agent.

• Cross-reactivity: Verify that the observed band is indeed CSTF1 using peptide competition assays or knockout/knockdown controls.

• Buffer systems: Different buffer systems (Tris-glycine vs. Bis-Tris) can affect protein migration patterns.

• Protein standards calibration: Ensure accurate calibration of molecular weight standards used for size estimation.

If persistent discrepancies exist, mass spectrometry analysis of the immunoprecipitated protein band can provide definitive identification and insights into any modifications affecting mobility.

How can CSTF1 antibodies be utilized in ChIP and ChIP-seq experiments to study RNA processing mechanisms?

CSTF1 antibodies can be valuable tools for chromatin immunoprecipitation (ChIP) and ChIP-seq experiments to investigate the co-transcriptional nature of RNA processing. Since CSTF1 interacts with the C-terminal domain (CTD) of RNA polymerase II , ChIP experiments can reveal its genome-wide distribution and association with transcription termination sites. When designing ChIP experiments with CSTF1 antibodies:

• Crosslinking optimization: Standard formaldehyde crosslinking (1% for 10 minutes) is typically sufficient, but optimization may be needed to capture transient CSTF1-chromatin interactions.

• Antibody selection: Choose antibodies validated for immunoprecipitation applications, such as those recommended for IP at 0.5-4.0 μg per 1.0-3.0 mg of total protein lysate .

• Controls: Include input chromatin, IgG control, and positive controls (ChIP for RNA Pol II) to validate the specificity of CSTF1 binding.

• Sequential ChIP (Re-ChIP): Consider Re-ChIP approaches to identify genomic regions where CSTF1 co-localizes with other 3' end processing factors or RNA Pol II.

• Data analysis: Focus analysis on regions surrounding transcription termination sites and correlate with RNA-seq data to connect CSTF1 binding with actual polyadenylation events.

• Cell type considerations: Since CSTF1 antibodies have been validated in multiple cell lines , select appropriate models based on the specific RNA processing events under investigation.

What are the considerations for using CSTF1 antibodies in studying stress-induced alterations in mRNA processing?

Cellular stress can significantly affect mRNA processing and polyadenylation patterns, making CSTF1 antibodies valuable tools for investigating these changes. When designing experiments to study stress-induced alterations:

• Stress conditions: Establish appropriate stress conditions (heat shock, oxidative stress, ER stress, etc.) with careful time course analysis to capture dynamic changes in CSTF1 localization or function.

• Subcellular fractionation: Combine CSTF1 immunoblotting with subcellular fractionation to detect stress-induced relocalization between nuclear and cytoplasmic compartments.

• Co-immunoprecipitation: Use CSTF1 antibodies for co-IP to identify stress-induced changes in CSTF1's interaction partners within the polyadenylation complex.

• Phosphorylation status: Consider using phosphorylation-specific antibodies or Phos-tag gels with CSTF1 antibodies to detect stress-induced post-translational modifications that may alter function.

• Alternative polyadenylation analysis: Combine CSTF1 immunoprecipitation with RNA-seq to identify stress-induced changes in polyadenylation site selection.

• Visualization approaches: Use immunofluorescence with validated dilutions (1:50-1:500) to monitor stress-induced changes in CSTF1 localization, particularly in relation to stress granules or other RNA processing bodies.

• Cell type considerations: Different cell types may exhibit unique stress responses, so compare results across validated cell lines like HeLa, HEK-293T, and A549 .

How can researchers incorporate CSTF1 antibodies in multiomic approaches to study RNA processing regulation?

Integrating CSTF1 antibodies into multiomic experimental designs can provide comprehensive insights into RNA processing regulation:

• ChIP-seq and RNA-seq integration: Combine CSTF1 ChIP-seq with RNA-seq to correlate CSTF1 binding sites with actual polyadenylation events and transcript abundance.

• Proteomics approaches: Use CSTF1 antibodies for immunoprecipitation followed by mass spectrometry (IP-MS) to identify the complete interactome of CSTF1 under different cellular conditions.

• Proximity labeling: Combine CSTF1 antibodies with techniques like BioID or APEX to identify proteins in close proximity to CSTF1 in living cells.

• CLIP-seq adaptations: Adapt CLIP-seq (Cross-linking immunoprecipitation sequencing) methods using CSTF1 antibodies to identify RNA sequences directly bound by the CstF complex.

• Single-cell approaches: Apply CSTF1 antibodies in single-cell protein analysis methods to investigate cell-to-cell variability in CSTF1 expression and localization.

• Spatial transcriptomics: Combine CSTF1 immunofluorescence with spatial transcriptomics to correlate CSTF1 localization with region-specific RNA processing events in tissues.

• Time-resolved studies: Implement pulse-chase experiments with CSTF1 immunoprecipitation to study the dynamics of complex assembly and disassembly during RNA processing.

When designing these multiomic approaches, researchers should select CSTF1 antibodies with appropriate validation for the specific techniques being integrated, considering the recommended applications and dilutions provided in the literature .